Research programme: monoclonal antibody therapeutics - JJP Biologics
Latest Information Update: 18 Nov 2022
At a glance
- Originator JJP Biologics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 03 Nov 2022 Monoclonal antibody therapeutics are available for licensing as of 03 Nov 2022. https://jjpbiologics.com/pipeline/
- 03 Nov 2022 Early research in Cancer in Poland (Parenteral) (JJP Biologics pipeline, November 2022)